Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + furmonertinib + bevacizumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intrathecal, Oral, Intravenous
01
Overview
A combination therapy consisting of pemetrexed (an antifolate antimetabolite), furmonertinib (a third-generation EGFR tyrosine kinase inhibitor), and bevacizumab (a recombinant humanized monoclonal IgG1 antibody that inhibits VEGF). This combination is being investigated for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) with leptomeningeal metastases, particularly after resistance to third-generation EGFR-TKIs. Pemetrexed may be administered intrathecally to increase intracranial drug concentrations, while high-dose furmonertinib (160mg daily) is used systemically along with bevacizumab (5-7.5 mg/kg) to target both the primary tumor and metastases.
- Brand names
- AlflutinibAvastinAlimta
- Other names
- furmonertinibfirmonertinib
02
Targets
DHFR (Dihydrofolate reductase)VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on pemetrexed + furmonertinib + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + furmonertinib + bevacizumab.